6533b7d4fe1ef96bd1262654

RESEARCH PRODUCT

Synthesis of 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-β-d-glucosyl)-purine: a novel radioligand for positron emission tomography studies of the O6-methylguanine-DNA methyltransferase (MGMT) status of tumour tissue

B WänglerBernd KainaGerd NagelFrank RöschEsther SchirrmacherJost ReinhardManfred WießlerUte MühlhausenMarkus PielRalf Schirrmacher

subject

PurineMethyltransferasemedicine.diagnostic_testOrganic ChemistryConjugated systemBiochemistryDNA methyltransferasedigestive system diseasesTumour tissuechemistry.chemical_compoundchemistryBiochemistryPositron emission tomographyDrug DiscoveryPyridineRadioligandmedicineneoplasms

description

Abstract The synthesis of the novel glucose conjugated O6-methylguanine-DNA methyltransferase (MGMT) inhibitor 2-amino-6-(2-[18F]fluoro-pyridine-4-ylmethoxy)-9-(octyl-α- d -glucosyl)-purine is reported. This compound might serve as a radiotracer for the determination of the MGMT status of tumour tissue.

https://doi.org/10.1016/s0040-4039(02)01394-1